These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 28854143)

  • 1. Biases in Individualized Cost-effectiveness Analysis: Influence of Choices in Modeling Short-Term, Trial-Based, Mortality Risk Reduction and Post-Trial Life Expectancy.
    van Klaveren D; Wong JB; Kent DM; Steyerberg EW
    Med Decis Making; 2017 Oct; 37(7):770-778. PubMed ID: 28854143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The costs and benefits of community thrombolysis for acute myocardial infarction : a decision-analytic model.
    Vale L; Steffens H; Donaldson C
    Pharmacoeconomics; 2004; 22(14):943-54. PubMed ID: 15362930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction.
    Kalish SC; Gurwitz JH; Krumholz HM; Avorn J
    J Gen Intern Med; 1995 Jun; 10(6):321-30. PubMed ID: 7562123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
    Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL
    N Engl J Med; 1995 May; 332(21):1418-24. PubMed ID: 7723799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of enoxaparin in acute ST-segment elevation myocardial infarction: the ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction 25) study.
    Marcoff L; Zhang Z; Zhang W; Ewen E; Jurkovitz C; Leguet P; Kolm P; Weintraub WS
    J Am Coll Cardiol; 2009 Sep; 54(14):1271-9. PubMed ID: 19778669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian cost-effectiveness analysis. An example using the GUSTO trial.
    Fryback DG; Chinnis JO; Ulvila JW
    Int J Technol Assess Health Care; 2001; 17(1):83-97. PubMed ID: 11329847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
    Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP
    J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the Value of Individualized Information: The Impact of Poor Calibration or Discrimination in Outcome Prediction Models.
    Olchanski N; Cohen JT; Neumann PJ; Wong JB; Kent DM
    Med Decis Making; 2017 Oct; 37(7):790-801. PubMed ID: 28399375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of early discharge after uncomplicated acute myocardial infarction.
    Newby LK; Eisenstein EL; Califf RM; Thompson TD; Nelson CL; Peterson ED; Armstrong PW; Van de Werf F; White HD; Topol EJ; Mark DB
    N Engl J Med; 2000 Mar; 342(11):749-55. PubMed ID: 10717009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy.
    Califf RM; Stump D; Topol EJ; Mark DB
    Am Heart J; 1999 May; 137(5):S90-3. PubMed ID: 10220606
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness analysis of short-term clopidogrel therapy for ST elevation myocardial infarction.
    Gibler KB; Huskamp HA; Sabatine MS; Murphy SA; Cohen DJ; Cannon CP
    Crit Pathw Cardiol; 2010 Mar; 9(1):14-8. PubMed ID: 20215905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction.
    Krumholz HM; Pasternak RC; Weinstein MC; Friesinger GC; Ridker PM; Tosteson AN; Goldman L
    N Engl J Med; 1992 Jul; 327(1):7-13. PubMed ID: 1598117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38.
    Mahoney EM; Wang K; Arnold SV; Proskorovsky I; Wiviott S; Antman E; Braunwald E; Cohen DJ
    Circulation; 2010 Jan; 121(1):71-9. PubMed ID: 20026770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of thrombolysis administered by paramedics.
    Scuffham PA; Tippett V
    Curr Med Res Opin; 2008 Jul; 24(7):2045-58. PubMed ID: 18544187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of streptokinase for acute myocardial infarction: A combined meta-analysis and decision analysis of the effects of infarct location and of likelihood of infarction.
    Midgette AS; Wong JB; Beshansky JR; Porath A; Fleming C; Pauker SG
    Med Decis Making; 1994; 14(2):108-17. PubMed ID: 8028463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of the cost effectiveness of treatment of acute myocardial infarct with primary angioplasty and thrombolysis ].
    Golán L; Simek S; Linhart A; Cahlík T; Palecek T; Lubanda JC; Korínek J; Beran S; Aschermann M
    Vnitr Lek; 2003 Feb; 49(2):97-102. PubMed ID: 12728575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of the cost-effectiveness of thrombolytic therapy in acute myocardial infarct using tissue plasminogen activator or streptokinase:the Italian perspective].
    Lorenzoni R; Fattore G; Gensini G
    G Ital Cardiol; 1997 Jul; 27(7):721-6. PubMed ID: 9303862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential Bias Associated with Modeling the Effectiveness of Healthcare Interventions in Reducing Mortality Using an Overall Hazard Ratio.
    Alarid-Escudero F; Kuntz KM
    Pharmacoeconomics; 2020 Mar; 38(3):285-296. PubMed ID: 31755032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dealing with discounting. An application to the cost-effectiveness of intracoronary thrombolysis with streptokinase.
    Martens L; van Doorslaer E
    Int J Technol Assess Health Care; 1990; 6(1):139-45. PubMed ID: 2113890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimated gain in life expectancy. A simple tool to select optimal reperfusion treatment in individual patients with evolving myocardial infarction.
    Boersma H; van der Vlugt MJ; Arnold AE; Deckers JW; Simoons ML
    Eur Heart J; 1996 Jan; 17(1):64-75. PubMed ID: 8682132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.